A Phase 4 interventional study of esomeprazole 40 mg in Heartburn, sponsored by AstraZeneca. Completed at 1 site in China. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2012-10-31.
Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing esomeprazole in Heartburn — none open to participants now, none under way, none of them phase 3. Esomeprazole · Heartburn.
Among the 19 studies testing esomeprazole in Heartburn, this one is the 12th largest by enrollment, is one of 2 that started in 2010, is one of 15 in phase 4, and was the 15th registered.
154 studies on the registry are indexed under Heartburn; 12 are open to participants now.
Browse Heartburn studies →None of the 19 studies testing esomeprazole in Heartburn is open now. The open studies under Heartburn, anywhere →
Esomeprazole: first FDA approval 2001 (NEXIUM), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 8 Heartburn studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2010.
This study's enrollment of 101 is close to the median of 100 across 127 interventional studies indexed under Heartburn.
Median enrollment 248 across the 19 interventional studies. Of the 18 that completed or were terminated, 7 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 5 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
24 studies in Heartburn by AstraZeneca: none open now, none under way, none of them phase 3. Of 24 finished, 8 (33%) have results posted.
Among the 24 studies in Heartburn by AstraZeneca, this one is the 14th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2010, is one of 12 in phase 4, and was the 21st registered.
AstraZeneca’s Heartburn studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 19 studies testing esomeprazole in Heartburn, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 24 in Heartburn:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
One arm: esomeprazole 40 mg
Drug: esomeprazole 40 mg
esomeprazole 40 mg once daily, 8 weeks
Also known as: No comparator
Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1)
The number of days with heartburn during the 7-day period prior to the 8 week visit (Visit 3) was compared to the number of days with heartburn during the 7-day period prior to baseline (Visit 1). The difference in the number of days with heartburn from baseline to 8 weeks was analysed.
Time frame: Baseline to 8 weeks
Change in the Frequency of Heartburn During the 7-day Period Prior to the 4 Week Visit (Visit 2) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1)
The number of days with heartburn during the 7-day period prior to the 4 week visit (Visit 3) was compared to the number of days with heartburn during the 7-day period prior to baseline (Visit 1). The difference in the number of days with heartburn from baseline to 4 weeks was analysed.
Time frame: Baseline and 4 weeks
Change in the Maximum Severity of Heartburn During the 7-day Period Prior to the 4 Week Visit (Visit 2) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1)
Maximum severity of heartburn during 7 days at baseline and at 4 weeks was obtained (None, Mild, Moderate, Severe). If the value at 4 weeks was better than at baseline in a participant, the participant was s categorized into "Improved". If the value was same, then categorised into "Unchanged". If the value was worsened, categorised into "Worsened".
Time frame: Baseline and 4 weeks
Change in the Maximum Severity of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1)
Maximum severity of heartburn during 7 days at baseline and at 8 weeks was obtained (None, Mild, Moderate, Severe). If the value at 8 weeks was better than at baseline in a participant, the participant was s categorized into "Improved". If the value was same, then categorised into "Unchanged". If the value was worsened, categorised into "Worsened".
Time frame: Baseline to 8 weeks
First participant enrolled on 23 November 2010. Last participant completed on 11 June 2011. Out of 101 enrolled participants, 100 participants (target was 100) received esomeprazole 40 mg. All of the participants were included in safety analysis set and 96 out of the 100 participants were included in the full analysis set for efficacy analyses.
| Milestone | Esomeprazole 40 mg |
|---|---|
| Started | 101 |
| Completed | 94 |
| Not completed | 7 |
| Withdrew: Withdrawal by subject | 4 |
| Withdrew: Adverse event | 1 |
| Withdrew: Protocol violation | 1 |
| Withdrew: Sponsor decision | 1 |
The number of days with heartburn during the 7-day period prior to the 8 week visit (Visit 3) was compared to the number of days with heartburn during the 7-day period prior to baseline (Visit 1). The difference in the number of days with heartburn from baseline to 8 weeks was analysed.
| Number of days | Arm 1 - Esomeprazole 40 mg |
|---|---|
| Change in the Frequency of Heartburn During the 7-day Period Prior to the 8 Week Visit (Visit 3) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1) | -3.3 ± 2.36 |
The number of days with heartburn during the 7-day period prior to the 4 week visit (Visit 3) was compared to the number of days with heartburn during the 7-day period prior to baseline (Visit 1). The difference in the number of days with heartburn from baseline to 4 weeks was analysed.
| Number of days | Arm 1 - Esomeprazole 40 mg |
|---|---|
| Change in the Frequency of Heartburn During the 7-day Period Prior to the 4 Week Visit (Visit 2) Compared to the Frequency of Heartburn During the 7-day Period Prior to Baseline (Visit 1) | -2.6 ± 2.82 |
Maximum severity of heartburn during 7 days at baseline and at 4 weeks was obtained (None, Mild, Moderate, Severe). If the value at 4 weeks was better than at baseline in a participant, the participant was s categorized into "Improved". If the value was same, then categorised into "Unchanged". If the value was worsened, categorised into "Worsened".
| Participants | Arm 1 - Esomeprazole 40 mg |
|---|---|
| Improved | 77 |
| Unchanged | 14 |
| Worsened | 1 |
Maximum severity of heartburn during 7 days at baseline and at 8 weeks was obtained (None, Mild, Moderate, Severe). If the value at 8 weeks was better than at baseline in a participant, the participant was s categorized into "Improved". If the value was same, then categorised into "Unchanged". If the value was worsened, categorised into "Worsened".
| Participants | Arm 1 - Esomeprazole 40 mg |
|---|---|
| Improved | 83 |
| Unchanged | 12 |
| Worsened | 1 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Esomeprazole 40 mg | — | 0/100 (0%) | 2/100 (2%) |
| Event | Esomeprazole 40 mg |
|---|---|
| NasopharyngitisInfections and infestations | 2/100 |
| Age Continuous(Year) | Esomeprazole 40 mg |
|---|---|
| Mean | 51.2 ± 13.71 |
| Sex: Female, Male(Participants) | Esomeprazole 40 mg |
|---|---|
| Female | 41 |
| Male | 60 |
The record gives a start of Nov 2010, a primary completion of Jun 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Esomeprazole